Regeneron Pharmaceuticals Inc

2026. nov. 14. 01:02 UTC

Regeneron Pharmaceuticals, Inc. is trading modestly higher in after-hours following a recovery from an earlier session dip, near the upper end of its one-month range.

2026. nov. 13. 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares are modestly higher in after-market trading following Friday's close, maintaining strong performance above its 20-day moving average.

2026. nov. 12. 21:07 UTC

Regeneron Pharmaceuticals, Inc. shares fell sharply after reaching an early peak, stabilizing near the upper end of its one-month range.

2026. nov. 11. 22:51 UTC

Regeneron Pharmaceuticals, Inc. shares are trading higher in after-market hours, currently positioned 11.58% above its 20-day moving average.

2026. nov. 10. 23:11 UTC

Regeneron Pharmaceuticals, Inc. shares advanced modestly in after-hours trading, reversing earlier losses and reaching the upper end of their one-month range.

2026. nov. 9. 21:07 UTC

Regeneron Pharmaceuticals reports positive results from its first-in-human trial of CIDEBsiRNA, with 93% of participants achieving significant liver fat reductions.

2026. nov. 6. 23:06 UTC

Regeneron Pharmaceuticals, Inc. shares are trading modestly lower in after-market hours, following a brief rise earlier in the session.

2026. nov. 5. 23:03 UTC

iShares Biotechnology ETF (IBB) is trading lower in after-market hours, with Regeneron Pharmaceuticals moving in sympathy with IBB amid mixed sector earnings results.

2026. nov. 4. 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares are advancing in after-market hours, following a strong performance and remaining significantly above their 20-day moving average.

2026. nov. 3. 23:02 UTC

Regeneron Pharmaceuticals, Inc. shares declined in after-market trading, pulling back from a brief high to a notable low point following strong performance in prior sessions.

2026. nov. 2. 23:02 UTC

Regeneron Pharmaceuticals plans to webcast management participation at upcoming investor conferences, including Jefferies on November 17 and Evercore on December 1, 2026.

2026. okt. 30. 23:06 UTC

Regeneron Pharmaceuticals, Inc. is trading modestly lower in after-market hours, reversing a trend of three consecutive higher daily finishes.

2026. okt. 29. 23:03 UTC

Regeneron Pharmaceuticals, Inc. is trading higher in after-market hours, reflecting strong performance since Thursday's close and reaching a notable peak during the session.

2026. okt. 28. 23:02 UTC

Canaccord Genuity maintains its Buy rating on Regeneron Pharmaceuticals and raises the price target to $922, contributing to after-market gains.

2026. okt. 26. 20:07 UTC

Regeneron Pharmaceuticals extends its agreement with BARDA to supply $270 million in additional doses of Inmazeb, ensuring delivery through 2031.

2026. okt. 23. 20:51 UTC

Regeneron Pharmaceuticals Inc shares rose during after-market hours, moving higher alongside the broader market amid mixed economic indicators and falling U.S. Treasury yields.

2026. okt. 22. 23:51 UTC

Regeneron Pharmaceuticals Inc is trading higher in after-market hours, maintaining a strong position above its 20-day moving average and near the upper end of its one-month range.

2026. okt. 21. 19:46 UTC

Regeneron Pharmaceuticals Inc shares fell.

2026. okt. 20. 23:02 UTC

Regeneron Pharmaceuticals Inc shares are declining in after-market trading, retracing earlier gains and positioned near the lower end of its recent trading range.

2026. okt. 19. 22:56 UTC

Regeneron Pharmaceuticals Inc. is trading modestly higher in after-market hours, maintaining gains above its 20-day moving average and near the upper end of its one-month range.

2026. okt. 16. 23:01 UTC

Regeneron receives positive opinion from the European Medicines Agency for an alternative dosing schedule for Libtayo® across all approved indications.

2026. okt. 15. 20:07 UTC

Regeneron Pharmaceuticals receives a UBS upgrade to Buy with a price target raised to $978, and partners with Sanofi to enhance Dupixent access in Canada.

2026. okt. 14. 20:02 UTC

Regeneron Pharmaceuticals Inc shares have risen sharply, supported by strong performance in the Biotechnology sector, remaining well above the previous close.

2026. okt. 13. 20:08 UTC

Regeneron Pharmaceuticals announces positive Phase 3 OPTIMA trial results for Pasatru™ in FOP patients, despite shares trading lower during Tuesday's session.

2026. okt. 12. 23:11 UTC

Regeneron Pharmaceuticals Inc is trading modestly higher in after-market hours, continuing a positive trend after three consecutive sessions of gains.

2026. okt. 9. 20:01 UTC

Regeneron Pharmaceuticals Inc is trading higher, having reached a peak earlier today while remaining below its 20-day moving average.

2026. okt. 8. 23:01 UTC

Regeneron Pharmaceuticals Inc is declining in after-market trading, moving lower since Thursday's close and approaching the lower end of its one-month range.

2026. okt. 7. 23:45 UTC

Regeneron Pharmaceuticals Inc traded roughly flat in after-market hours, retracing from a post-close peak and remaining below its 20-day moving average.

2026. okt. 6. 23:30 UTC

Regeneron Pharmaceuticals Inc. is trading modestly lower in after-market hours, continuing a downward trend and positioned near the lower end of its one-month range.

2026. okt. 5. 23:05 UTC

Regeneron Pharmaceuticals Inc saw a slight gain in after-market trading, following a flat regular session, but remains below its 20-day moving average.